NCT03677557 - Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 19, 2018

Primary Completion Date

August 31, 2021

Study Completion Date

August 31, 2021

Conditions

Primary Immunodeficiency DiseaseSecondary Immunodeficiency

Interventions

DRUG

16,5% Cutaquig

Participants with primary or secondary immunodefiiciney disease and who do not tolerate other immunoglobulin treatments will be asked to use 16.5% Cutaquig

Trial Locations (1)

K1H 8L6

RECRUITING

The Ottawa Hospital, General Campus, Ottawa